ACTION @ ISHLT ’23: Taking ACTION: Creation of a Prospective Registry of Boys with Dystrophinopathy and Ventricular Dysfunction to Define Cardiac Medication Use And Optimize Guideline Directed Medical Therapy
Abstract Now Available!
Muscular Dystrophy
Initial Multicenter Experience with Ventricular Assist Devices in Children and Young Adults with Muscular Dystrophy: An ACTION Registry Analysis
Purpose Cardiac disease results in significant morbidity and mortality in patients with muscular dystrophy (MD). Single centers have reported their ventricular assist device (VAD) experience in specific MDs and in
Current Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD): Understanding Care Practices in Order to Optimize DMD Heart Failure Through ACTION
The results of an ACTION-wide survey of pediatric cardiology providers are detailed in the latest ACTION publication, Current Practices in Treating Cardiomyopathy and Heart Failure in Duchenne Muscular Dystrophy (DMD):
Parent Project Muscular Dystrophy (PPMD) funds ACTION to expand Muscular Dystrophy collaboration efforts
ACTION receives $2 million grant from Parent Project Muscular Dystrophy (PPMD) to expand muscular dystrophy focused research and quality improvement initiatives
Muscular Dystrophy
Patients with Muscular Dystrophy (MD) have weakened muscles; this also includes their heart muscle. These patients may develop signs and symptoms of heart failure and may need treatment such as cardiac medicines, mechanical devices, or advanced treatments.
Muscular Dystrophy Read More »
